| Aktientyp | Stammaktie |
Gilead übernimmt Forty Seven für 4,9 Mrd. $
https://www.fiercebiotech.com/biotech/gilead-strikes-4-9b-forty-seven-acquisition-paying-a-hefty-premium-for-cancer-drug
Übernahmephantasie
https://www.fiercebiotech.com/biotech/gilead-hungry-for-don-t-eat-me-cancer-biotech-reports
https://www.benzinga.com/general/biotech/20/02/15440578/gilead-eyes-takeover-of-cancer-biotech-forty-seven-report
Übernahmegerüchte durch Gilead Sciences
https://seekingalpha.com/news/3546878-gilead-sciences-approaches-forty-seven-takeover-deal-bloomberg